Immunotherapy grants

Main applicant must be an established investigator with primary employment at a university, hospital, or non-profit research institution in a Nordic country (Denmark, Sweden, Norway, Finland, Iceland, Greenland, Faroe Islands). Translational/applied focus on regenerative medicine (stem cell-based therapies); fundamental discovery, adult immune cell (CAR-T/NK), and gene therapy projects are out of scope. For-profit partners may collaborate but cannot receive direct funding (subcontractors excepted).

Open to postdoctoral researchers with a doctoral degree and <5 years of mentored research experience (M.D. applicants exclude residency years). Research must be in immunology or cancer immunology at a non-profit institution worldwide. No citizenship restrictions. Sponsor must hold assistant professor rank or higher. Only 1 fellow per sponsor per round.

Open to early-career scientists worldwide (<5 years mentored research post-PhD at award activation) at non-profit institutions. Supports dual training in cancer immunology and computational biology/data science. No citizenship restrictions. Must be conducted under a sponsor holding assistant professor or higher rank. Proposals must be hypothesis-driven in basic or translational cancer immunology.

Funds human-centric mechanistic experimental medicine studies testing hypotheses about disease mechanisms using interventions (compounds, biologics, psychological, physiological, vaccines, immune challenges). Requires human participant recruitment with clinical infrastructure. New Investigator Award track available. Applications in English; UK institutions. No matched funding requirement beyond standard 20% FEC.

Pilot grant addressing an emerging gap in support for new clinical trials in DIPG. Funds hiring of a clinical fellow to support clinical trial work (e.g., CAR-T cell trials). First-time award; check the grant application page for future availability.

Supports pioneering immunotherapy clinical trials designed and led by academic researchers. Requires clinical trial focus; applicants must be academic investigators. Protocol concept submission required as first stage.

For mid-career cancer immunotherapy researchers: tenure-track assistant professors (≥3 years in role) or associate professors (≤3 years in role) with MD, PhD, or MD/PhD. Minimum 80% time commitment to research. Open internationally; research may be conducted at medical schools or research centers worldwide, but NOT at for-profit institutions. No citizenship restrictions. Unrestricted, flexible funding for high-risk, high-reward cancer immunotherapy research.

For mid-career scientists (tenure-track assistant professors ≥3 years or associate professors ≤3 years in role) with MD, PhD, or MD/PhD. Minimum 80% research commitment required. Open globally; host institution must be a non-profit medical school or research centre (no for-profit institutions). No citizenship restrictions. Funds high-risk, high-reward cancer immunotherapy research.

Supports innovative investigations at the intersection of laboratory discovery and clinical application in cancer immunology. Requires integration of clinic and laboratory research; clinical/patient-sample involvement likely. LOI required as first stage.

Supports early-stage, pre-development concepts with potential to transform cancer immunotherapy. Targets bold, innovative technology ideas at an early/pre-development stage. LOI required as first stage.

Supports the transition of distinguished postdoctoral researchers into independent tenure-track investigators in cancer immunotherapy. Targets researchers at the postdoc-to-faculty transition stage.

Pilot data generation and hypothesis-driven mechanistic studies examining inflammatory and immune processes in neurological conditions and mental illness. Excludes GWAS/epidemiological studies and MS-only projects. Funded at 80% full economic cost; PhD studentship costs not eligible. UK institutions; principal investigator CV and key publications required at expression of interest stage.